Glaukos Corporation · NYSE:GKOS
Glaukos — Investor Presentation (May 2022)
28 slides from Glaukos's investor presentation, May 23, 2022
Slide 1: Investor Presentation May 2022
Investor Presentation MAY 2022
Slide 2: Disclaimer
2 © 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward - looking statements . These statements are
Slide 3: oration ǀ Privileged, & Proprietary ǀ For Internal Use Only
3 © 2022 Glaukos Corporation 3 © 2021 Glaukos Corporation ǀ Privileged, Confidential & Proprietary ǀ For Internal Use Only
Slide 4: Attractive Financial Profile Provides Solid Foundation
4 © 2022 Glaukos Corporation Attractive Financial Profile Provides Solid Foundation SCALE MARGINS DIVERSIFICATION BALANCE SHEET $46 … 7 - Yr CAGR: 30% 2014 2021 TOTAL NET SALES ( in millions ) $294 2022 75% 83% 2014 1 FY2014 GAAP & non - GAAP gross margin (75%); 1Q 2022 GAAP gross margin of 75% was
Slide 5: 2022: Entering the Next Phase of Our Pioneering Journey
5 © 2022 Glaukos Corporation 2022: Entering the Next Phase of Our Pioneering Journey CORE FRANCHISES NEAR - TERM PIPELINE NEW R&D PLATFORMS & PROGRAMS GLOBAL ORGANIZATION Expanding Core Offering & Potential • Combo - cataract evolution • Standalone glaucoma entry • International glaucoma, iLink mark
Slide 6: Our Strategy for Long-Term Growth & Value Creation
6 © 2022 Glaukos Corporation 1 2 3 4 5 6 Novel Technology Platforms Leverageable Commercial Platform 1. SIGNIFICANT CLINICAL NEEDS 2. BIG IDEAS 3. SELF - FUNDING R&D TO DATE 4. EFFICIENT COMMERCIAL CHANNEL 5. PROVEN MARKET CREATOR 6. OPERATIONAL EXCELLENCE Our Strategy for Long - Term Growth & Value
Slide 7: Big Ideas: Disrupting Legacy Topical Eye Drop Therapy
7 © 2022 Glaukos Corporation Big Ideas: Disrupting Legacy Topical Eye Drop Therapy Topical eye drops are often ineffective due to significant patient non - adherence • Complex dosing regimens that are difficult to follow • Forgetfulness • Instillation challenges • Impositions to quality of life • Oc
Slide 8: Our Novel Technology Platforms
8 © 2022 Glaukos Corporation Our Novel Technology Platforms 6+ programs with key regulatory milestones in 2022 R&D INVESTMENT SINCE 2018 300M + $ DISCLOSED PIPELINE PROGRAMS 16 2015 2022 4 5 technologically distinct platforms Pharma innovations dominate Advancing the standard of care across our 3 fr
Slide 9: Unique Features of Our Differentiated Platforms
9 © 2022 Glaukos Corporation All platforms disrupt traditional paradigms and are designed to generate multiple innovations that offer advantages over the current standards of care (not a single eye drop) Unique Features of Our Differentiated Platforms Pioneering firsts: Maximizing proven ability to
Slide 10: Designed to Generate Layers of Future Growth
10 © 2022 Glaukos Corporation 2021 2030+ US MARKET OPPORTUNITY 1 $2B $60B iAccess iPRIME iStent infinite iDose TR Epioxa (Epi - on) iLution Dry Eye iLution Presbyopia iDose TREX Retina XR: MKI iLink Third Gen Retina XR: Triamcinolone iDose ROCK iLution Blepharitis IOP Sensor + + + A decade - long ca
Slide 11: Delivered Through Our Leverageable Commercial Platform
11 © 2022 Glaukos Corporation Delivered Through Our Leverageable Commercial Platform 2014 2022 COUNTRIES WITH DIRECT SALES 2 17 $225 Efficient, scalable platform ready to provide a range of quality products and services across a growing global customer base NEAR - TERM PIPELINE PRODUCTS COMING INTO
Slide 12: iStent Platform: MIGS Pioneer & Innovation Leader
12 © 2022 Glaukos Corporation 1M iStent devices implanted worldwide iStent Platform: MIGS Pioneer & Innovation Leader PRODUCT/PROGRAM PATIENT STATUS iStent / iStent inject / iStent inject W Mild - to - Moderate Glaucoma with Cataract Approved (2012 / 2018 / 2020) iStent infinite Refractory Glaucoma
Slide 13: iAccess Launched in Q1 2022
13 © 2022 Glaukos Corporation iAccess Ρ Launched in Q1 2022 iAccess is designed to deliver multiple outflow channels through the trabecular meshwork into Schlemm’s canal When medically necessary, precision goniotomy with iAccess is designed to be unrestricted in its ability to create numerous ectomi
Slide 14: iPRIME Receives FDA Clearance
14 © 2022 Glaukos Corporation iPRIME Ρ Receives FDA Clearance iPRIME is a minimally invasive viscoelastic delivery system that further supports the needs of physicians and patients This complementary technology further expands Glaukos’ broad portfolio of innovative ophthalmic solutions A viscoelasti
Slide 15: iStent infinite: Powerful Standalone MIGS Indication
15 © 2022 Glaukos Corporation iStent infinite: Powerful Standalone MIGS Indication iStent infinite is not approved by the FDA CLINICAL TRIAL RESULTS 1 76 of subjects achieved 20% or greater reduction in mean diurnal IOP from baseline on same or lower ocular hypotensive medication burden 13 ≥ 50 of s
Slide 16: iDose Platform: The Next Stage in Glaucoma Therapy
16 © 2022 Glaukos Corporation iDose Platform: The Next Stage in Glaucoma Therapy PROGRAM PATIENT STATUS iDose TR OHT - Refractory Glaucoma Phase 3; NDA filing targeted for 2022 iDose TREX OHT - Refractory Glaucoma Pre - clinical iDose Rock OHT - Refractory Glaucoma Pre - clinical DISCLOSED PIPELINE
Slide 17: iDose TR: Phase 2b Data at 36 Months
17 © 2022 Glaukos Corporation iDose TR: Phase 2b Data at 36 Months ~ 70% were responders well controlled on iDose with the same or fewer topical IOP - lowering meds at 36 months vs screening, including patients on 2 and 3 meds at screening RESPONDER AVERAGE IOP REDUCTION FROM BASELINE iDose TR is no
Slide 18: iDose TR: Phase 2b Data at 36 Months (Tolerability)
18 © 2022 Glaukos Corporation Well - tolerated • No ocular hyperemia (30 - 50%+ for topical PGAs) • No periorbital fat atrophy (up to 70% incidence for topical PGAs) • No clinically significant corneal endothelial cell loss • Only 1 instance of iris color change (~20% incidence for topical PGAs) iDo
Slide 19: iLink Platform: Bio-Activated Pharmaceuticals
19 © 2022 Glaukos Corporation iLink Platform: Bio - Activated Pharmaceuticals PRODUCT/ PROGRAM PATIENT STATUS Photrexa (Epi - off) Keratoconus Approved (2016) Epioxa (Epi - on) Keratoconus Phase 3; NDA filing targeted for 2022 iLink Third - Generation Keratoconus Phase 2; actively enrolling COMMERCI
Slide 20: Epioxa (Epi-on): Phase 3 Trial Achieved Primary Efficacy Outcome
20 © 2022 Glaukos Corporation Epioxa (Epi - on): Phase 3 Trial Achieved Primary Efficacy Outcome - 1.0D Achieved primary efficacy outcome by demonstrating Kmax treatment effect of Well - tolerated procedure (majority of adverse events were mild and transient in nature; no change in corneal endotheli
Slide 21: iLution Platform: Transdermal Dropless Therapy
21 © 2022 Glaukos Corporation iLution Platform: Transdermal Dropless Therapy PROGRAM PATIENT STATUS iLution Dry Eye Dry Eye Phase 2: actively enrolling iLution Presbyopia Presbyopia Phase 2: actively enrolling iLution Blepharitis Demodex Blepharitis Pre - clinical Anterior Segment Candidates Glaucom
Slide 22: Retina XR Platform: Addressing Conventional Therapy Drawbacks
22 © 2022 Glaukos Corporation Retina XR Platform: Addressing Conventional Therapy Drawbacks PROGRAM PATIENT STATUS IVT Multi - Kinase Inhibitor AMD, DME Pre - clinical IVT Triamcinolone DME Pre - clinical DISCLOSED PIPELINE PROGRAMS Targeting biodegradable, small - molecule implant with 6 - 12 month
Slide 23: Retina XR Candidate: Multi-Kinase Inhibitor
23 © 2022 Glaukos Corporation Retina XR Candidate: Multi - Kinase Inhibitor FA LEAKAGE CHANGE FROM BASELINE IN MULTI - KINASE INHIBITOR CANDIDATE AND PLACEBO - TREATED DL - AAA EYES Leveraging 20+ years of injector system development expertise 0 2 8 5 6 8 4 1 1 2 1 4 0 1 6 8 1 9 6 2 2 4 2 5 2 2 8 0
Slide 24: Commercial Execution in the Areas Most Visible to Investors
24 © 2022 Glaukos Corporation Commercial Execution in the Areas Most Visible to Investors… Under the Surface: Photrexa (Epi - off) Combo - Cataract 30% 7 - Year CAGR
Slide 25: ...While Our Future is Just Beginning to Be Revealed
25 © 2022 Glaukos Corporation …While Our Future is Just Beginning to Be Revealed Photrexa (Epi - off) Combo - Cataract Standalone Therapies OHT - Refractory Epioxa (Epi - on) Disruptive Programs For Glaucoma Dry Eye Presbyopia Keratoconus Blepharitis AMD, DME Photrexa (Epi - off) Combo - Cataract iS
Slide 26: Summary: Glaukos is Different
26 © 2022 Glaukos Corporation Summary: Glaukos is Different Delivering disruptive dropless therapies designed to improve patient outcomes Five distinct technology platforms, dominated by pharmaceuticals and designed to generate waves of new market - expanding products Pursuing game - changing therap
Slide 27: Glaukos: Transforming Vision
GLAUKOS TRANSFORMING VISION
Slide 28: Appendix: GAAP to Non-GAAP Reconciliation - 1Q 2022
28 © 2022 Glaukos Corporation Appendix Amort. of Stock-based Dev Tech Comp Exp on 1Q 2022 GAAP Intangibles Replacement 1Q 2022 Non-GAAP Gross Margin Awards Gross Margin Net Sales 67,681$ 67,681$ COGS 17,063$ (5,523)$ (28)$ 11,512$ Gross Profit 50,618$ 5,523$ 28$ 56,169$ Gross Margin 75% 83% GAAP to